Is Polaryx Therapeutics going out of business?

Polaryx Therapeutics, Inc. (PLYX) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Polaryx Therapeutics, Inc. (PLYX) fundamentals, assembled from SEC filings.

Five questions, kept separate

Survival - Fragile

15-21 mo of estimated runway from 2026-06-30, based on $11.5M of cash and short-term investments against $7.8M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Evidence incomplete

The current price is available, but the filing does not contain enough applicable valuation evidence to interpret it.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Filing event risk: Going-Concern Warning (-8 pts)
• Return on Assets: -76.07%
• Price / Earnings: Unprofitable (see Valuation)
• Shares dilution YoY: 7.29% (YoY)
• Effective Tax Rate: 0.00% (loss-making)

Read from filings through 2026-08-13.

Price as of 2026-09-09.